Timing note: July 22, 2026 is today, not tomorrow. PMI is scheduled to report 2Q26 results before the U.S. market open, followed by its 2026Q2 earnings call.
PM enters earnings with a strong fundamental setup but elevated expectations. The investment case remains centered on continued international IQOS momentum, structurally favorable smoke-free mix, pricing power in combustibles, and a potential second-half improvement in the U.S. nicotine-pouch business as ZYN comparisons normalize and innovation reaches the market.
The near-term debate is less about whether PMI can post a solid quarter—it guided to it—and more about whether it can reaffirm or raise its full-year outlook while demonstrating that the U.S. ZYN growth slowdown is manageable. Consensus expectations appear to be near the top end of PMI’s own 2Q adjusted EPS guide, which raises the bar for the stock reaction.
PM shares closed at $188.07 on July 21, up roughly 17% year to date and near their recent July high of $192.98. That performance suggests investors will likely require a clean beat, strong qualitative U.S. commentary, or a guidance lift rather than merely an in-line result.
| Metric | PMI 2Q26 guidance / current expectation |
|---|---|
| Adjusted diluted EPS | $2.02–$2.07 |
| Street EPS expectation | ~$2.07 |
| Organic net-revenue growth | Mid-single digits; Street ~5% |
| Smoke-free revenue growth | Street ~10% |
| HTU shipment volume | 40–42 billion units |
| Cigarette shipment volume | Low-single-digit decline |
| Full-year adjusted EPS guidance | $8.36–$8.51 |
| Full-year organic revenue growth | 5%–7% |
| Full-year organic operating-income growth | 7%–9% |
| Full-year currency-neutral adjusted EPS growth | 7.5%–9.5% |
The key nuance is that PMI’s 2Q EPS guide included only about a $0.02 FX benefit, while its full-year guide assumed a larger $0.25 currency tailwind at prevailing rates when guidance was reaffirmed in April. Investors should distinguish genuine operational upside from FX-driven revisions.
PMI’s first quarter showed why the market has rewarded the company: international smoke-free revenue grew 15.8% organically, smoke-free gross profit grew 19.4% organically, and international smoke-free gross margin reached 70.0%.
The underlying drivers were broad-based:
For 2Q, the most important question is whether IQOS growth remains near double digit despite a tougher Japan comparison. Management had explicitly flagged that Japanese consumer pantry loading ahead of an April 1 excise-related price increase benefited 1Q by about 0.5 billion HTUs, and that 2Q adjusted in-market-sales growth would slow as this effect reverses.
Read-through: a moderation in Japan is expected; a material deceleration outside Japan would be more concerning.
The U.S. business disappointed in 1Q, but the weakness was largely attributable to inventory, promotional, and investment dynamics rather than a collapse in consumer demand:
The concern is that recent category and ZYN scanner trends have moderated, while PMI’s portfolio lacks exposure to some faster-growing high-strength and flavor segments. Management has argued that upcoming innovation—including ZYN Ultra, subject to FDA authorization—should improve the brand’s competitive positioning in the second half.
A credible second-half U.S. improvement is central to maintaining the full-year growth algorithm. Conversely, another quarter of decelerating ZYN offtake or delayed innovation could lead investors to question the 2026 EPS back-half weighting.
PMI’s cigarette business remains an important cash and profit contributor, even as the smoke-free mix expands. In 1Q, international combustible volume declined 5.1%, but organic revenue still increased 1.0% and gross profit rose 3.9%, driven by 8.5% pricing and cost management.
For the full year, management expects:
The 2Q guide assumes a low-single-digit cigarette shipment decline, a meaningful improvement from 1Q. Investors should focus on whether this moderation materialized and whether pricing remains sufficient to protect revenue and profit after considering consumer pressure, illicit trade, excise changes, and share trends in markets such as Indonesia, Mexico, Germany, Russia, and Turkey.
Key risk: exceptional first-quarter pricing may normalize in the second half, particularly against tougher comparisons. A better-than-expected 2Q combustible result would reinforce the durability of PMI’s pricing power; weaker volume or share could make the full-year pricing/volume equation more difficult.
The structural bull case is not just smoke-free growth—it is smoke-free growth that is increasingly profitable. PMI posted a 1Q adjusted operating-income margin of 41.1%, up 40 basis points year over year, despite commercial reinvestment.
For 2Q, margin performance may be less clean because PMI has signaled another quarter of heavy investment behind commercial programs, innovation, manufacturing capacity, and U.S. growth. Management expects investment intensity to moderate in the second half and stated that full-year SG&A growth should be at or below organic revenue growth.
What matters most:
Balance-sheet leverage is manageable but remains relevant. At March 31, PMI had $51.9 billion of total debt and $46.5 billion of net debt, equivalent to 2.61x adjusted EBITDA. This makes sustained cash generation and disciplined capital allocation important, particularly alongside the company’s progressive-dividend commitment.
PMI reaffirmed its full-year outlook in April after a strong first quarter:
A simple reaffirmation would be understandable given Japan’s 2Q timing effects, ongoing U.S. uncertainty, global macro conditions, excise-tax developments, and potential logistics/input-cost effects from Middle East disruption. However, with the quarter expected to show a sequential improvement and the stock trading near highs, the market may be looking for either:
This is likely Emmanuel Babeau’s final earnings call as PMI CFO. Massimo Andolina, currently President of PMI’s Europe Region, is scheduled to become Group CFO effective August 1, 2026; Babeau will remain with PMI as a strategic adviser to CEO Jacek Olczak through March 31, 2027.
The transition should not alter the company’s strategy, but investors may listen for Andolina’s priorities on capital allocation, margins, smoke-free investment, and leverage.
PMI’s operational model remains attractive: smoke-free products are becoming a larger, higher-margin portion of the business while the combustible franchise continues to monetize through pricing. The crucial near-term issue is whether the company can turn its U.S. narrative from “inventory and comparison headwinds” into demonstrable renewed growth.
International IQOS execution should provide a solid floor for the quarter. But with consensus EPS near the top of guidance and the stock close to recent highs, the most important variables for the share reaction are likely to be ZYN’s current trajectory, U.S. innovation visibility, and the credibility of second-half acceleration—not simply the reported EPS result.
Sources reviewed: PMI 1Q26 earnings call and financial supplement; PMI 1Q26 Form 10-Q; July 2026 CFO-transition Form 8-K; recent PM market-news and price data.